Clinical Trial Update: An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 [Phase 1]

View source ↗

Summary

An open-label Phase 1 pharmacokinetic study of BIA 2-093 in epilepsy has completed, and its results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• BIA 2-093

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Epilepsy | Phase 1 | Status: COMPLETED | Results posted: 2015-01-12